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Background: There is no standard therapeutic procedure for the hepatocellular carcinoma (HCC) in patients with
poor hepatic reserve function. With the approval of newly developed chemotherapeutic agent of miriplatin, we have
firstly conducted the phase I study of CDDP powder (DDP-H) and miriplatin combination therapy and reported its
safety and efficacy for treating unresectable HCC in such cases. To determine the maximum tolerated dose (MTD)
and dose-limiting toxicity (DLT) for the combination of transarterial oily chemoembolization (TOCE) and transarterial
chemotherapy (TAC) using miriplatin and DDP-H for treating unresectable hepatocellular carcinoma (HCC).
Methods: Transarterial chemotherapy using DDP-H was performed through the proper hepatic artery targeting the
HCC nodules by increasing the dose of DDP-H (35–65 mg/m2) followed by targeting the HCC nodules by
transarterial oily chemoembolization with miriplatin.
Results: A total of nine patients were enrolled in this study and no DLT was observed with any dose of DDP-H in all
cases in whom 80 mg (median, 18–120) miriplatin was administered. An anti-tumour efficacy rating for partial
response was obtained in one patient, while a total of four patients (among eight evaluated) showed stable disease
response, leading to 62.5% of disease control rate. The pharmacokinetic results showed no further increase in plasma
platinum concentration following miriplatin administration.
Conclusion: Our results suggest that a combination of DDP-H and miriplatin can be safely administered up to their
respective MTD for treating HCC.
Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR000003541).
Keywords: Miriplatin, Hepatocellular carcinoma, Cisplatin powder, Phase I clinical trialBackground
Hepatocellular carcinoma (HCC) is the most common
type of liver cancer [1] and various therapeutic options
have been developed by focusing on the specific tumour
stage and hepatic functional reserve [2-9]. A variety of
transarterial treatments have been provided to cases at
relatively advanced stages [3], and these treatments were
roughly divided into the following three groups: tran-
sarterial chemoembolization (TACE), transarterial oily* Correspondence: suda@med.niigata-u.ac.jp
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reproduction in any medium, provided the orchemoembolization (TOCE) and transarterial chemo-
therapy (TAC), based on the likelihood of deteriorating
hepatic reserve. TACE involves hepatic arterial injections
of chemotherapeutic agents combined with embolizing
materials. TOCE is solely an arterial administration of a
combination of chemotherapeutic agents and oily con-
trast medium of lipiodol ultra fluid (Laboratory Guerbet,
Aulnay-sous-Bois, France), while in TAC, chemothera-
peutic agents alone are infused through the hepatic ar-
tery. Although TACE is only a transarterial procedure,
for which therapeutic efficacy has been proved in rando-
mised prospective controlled studies, the deterioration of
hepatic reserve is estimated at 20%–58%, mainly becausetral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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liver [10,11], inferring a higher risk of unfavourable re-
duction in hepatic reserve function in cases with poor
hepatic reserve. Therefore, to develop a safe and efficient
transarterial therapeutic procedure in such cases, other
effective means of performing TOCE, TAC, and TOCE +
TAC have been tested [5,12-15].
TACE and TOCE were recently compared in a rando-
mised phase III trial using zinostatin stimalamer dissolved
in lipiodol [12] with subsequent arterial embolization
(TACE) or without embolization (TOCE). Interestingly,
the results showed no improvement in survival rates by
performing embolization and TOCE represented to be a
therapeutic option for HCC patients with low hepatic re-
serve. However, two major concerns with TOCE are:
1) the method of combining water-based chemotherapeu-
tic agents with oily lipiodol in a stable formulation; and
2) that TOCE is unable to target wide area of the liver as
it reduces the hepatic arterial flow, although tentative, that
may result in hepatic failure. For first concern, Miriplatin,
a third-generation platinum derivative with lipophilic moi-
ety that forms a suspension with lipiodol, was recently
developed and approved for clinical use in Japan as a
novel chemotherapeutic agent for HCC [16-21] with
promising results [22-24]. For second concern, as TAC
requires no embolization, that can be injected in wide
area and its anti-tumour effect has been reported in
several studies [5,13-15], followed by the promising
results from a multicentre phase II study in patients
with unresectable HCC using cisplatin (CDDP), a
first-generation platinum agent, in which the response
rate was recorded as 33.8% [13], it might be effective
to treat wide area of the liver with poor hepatic re-
serve function. In addition, the first-pass kinetics [25]
of CDDP by TAC contribute to the anti-tumor effect
and decrease the adverse systemic events [5]. Since
highly concentrated CDDP powder for TAC (DDP-H,
IA-call
W
; Nippon Kayaku Co., Ltd) is available in
Japan, TAC is now widely used in Japan to treat mul-
tiple small tumours or patients with poor hepatic re-
serve [5,13,26].
Based on these results and the advances in the devel-
opment of new chemotherapeutics, it is reasonable to
consider the combination therapy of CDDP-TAC with
miriplatin-TOCE to treat advanced stage HCC with
poor hepatic reserve function safely and effectively.
Therefore, in this study we conducted a phase I dose-
escalation study on DDP-H-TAC followed by miriplatin-
TOCE to determine the maximum tolerated dose
(MTD) and dose-limiting toxicity (DLT) in unresect-
able HCC. The safety issue with regard to the combin-
ation of two platinum-based chemotherapeutic agents
will be discussed by referencing the pharmacokinetics
of platinum.Methods
Patient selection
Patients with HCC were considered eligible for the study
if they fulfilled the following criteria: 20–80 years of age;
at least one measurable tumour blush on angiography;
histologically and/or clinically diagnosed HCC; no other
therapeutic treatment was found to be effective or appro-
priate to their condition, according to the Japanese
guidelines for HCC treatment; an Eastern Cooperative
Oncology performance status of 0–2; adequate hepatic
function (Child–Pugh, score ≤7; total bilirubin, ≤3.0 mg/dl;
albumin, ≥3.0 g/dl); adequate haematological function
(neutrophils, ≥1,500/mm3; platelets, ≥50,000/mm3; haemo-
globin, ≥8.0 g/dl); adequate renal function (creatinine clear-
ance, ≥50 ml/min adjusted for 1.73 m2 of body surface
area); serum amylase, ≤324 IU/dl and an interval of 4 weeks
or more since previous therapy.
All nodules were radiologically diagnosed as HCC
when they satisfied at least one of the following criteria
based on CT or MRI: typical haemodynamics of classical
HCC (substantial enhancement during arterial phase
followed by a washout with ‘corona-like’ peripheral en-
hancement in equilibrium phase) and similar characteris-
tics of coexisting nodules that had been diagnosed as
HCC. All eligible HCC cases were recurrent with a his-
tory of CDDP administration in eight patients. Patients
with the following characteristics were considered ineli-
gible: massive pleural effusion and/or ascites refractory
to treatment; active cancer other than HCC; active infec-
tious disease; active haemorrhagic state; severe mental
disorder; hepatic encephalopathy; history of allergic reac-
tion to iodine phase contrast and/or platinum agents; on-
going interferon therapy and difficulty with oral food
intake. This study was approved by the institutional re-
view board of Niigata University Hospital and was regis-
tered with the University Hospital Medical Information
Network Clinical Trials Registry (UMIN-CTR 000003541).
Written informed consent was obtained from all patients
and the study protocol conformed to the ethical guidance
of the 1975 Declaration of Helsinki.
Method of administration
CDDP powder, DDP-H (Nippon Kayaku Co., Ltd. Tokyo,
Japan), was solubilised in saline at a concentration of
100 mg/70 ml immediately before use and infused into
the entire liver through the proper hepatic artery at a rate
of 126 ml/h, providing in total 35 mg/m2. This was fol-
lowed by TOCE with miriplatin, prepared according to
the instructions, through the nutrient vessels of the tar-
get tumour using a maximal dose showing corresponding
drainage portal veins up to a volume of 6 ml. If no DLT
was recorded, the same regimen was carried out by
increasing DDP-H by 15 mg/m2, based on the modified
Fibonacci method in which DLT is defined as adverse
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haematological toxicity, according to the NCI-CTCAE
version 4.0. If any of the three patients showed as having
DLT, three more patients were enrolled. MTD was
judged to have been exceeded when two patients showed
DLT. MTD was defined as the maximum dose where no
more than two of the six patients experienced DLT. If
two or more cases were already suffering from DLT at
the initial dose of 35 mg/m2, this dose was reduced by
10 mg/m2 to 15 mg/m2.Evaluation of anti-tumour effects
Anti-tumour response was evaluated from CT images
obtained before and 3 months after treatment. Evalu-
ation was performed in accordance with the modified
Response Evaluation Criteria in Solid Tumors (RECIST)
guideline, a new response evaluation criteria in solid
tumours [27]. The tumour markers of AFP and DCP
were followed at appropriate time periods for each
patient.Table 1 Patient characteristics
Group Level 1
CDDP (mg/m2) 35
Case number 1 2 3
Age (years) 80 62 80
Gender (M, Male/F, Female) M M M
Performance status 1 0 0
HBV infection - - -
HCV infection + + -
Alcohol - - +
Autoimmune hepatitis - - -
Child-Pugh Score 6 6 5
Recurrence (Y, Yes/N, No) Y Y Y
Interval to previous therapy (M) 6 8 6
Previous therapy TACE TAC TACE
History of CDDP Administration Y Y N
Number of tumors 3 2 1
Maximum tumor size (mm) 15 15 14
Vascular invasion (Y, Yes/N, No) N N N
Metastasis (Y, Yes/N, No) N N N
Stage (UICC) II II I
Tumor location (PAMLC) PA ML ML
BSA (m2) 1.486 1.6 1.457
Ccr (ml/min) 68 118 75
CDDP (mg/body) 52 56 51
Miriplatin (mg/body) 86 18 80
TACE, transarterial chemoembolization; TAC, transarterial chemotherapy. Tumour lo
segment; C, caudal segment. BSA, body surface area; Ccr, creatinine clearance.Platinum pharmacokinetics
Total plasma platinum concentration was measured and
pharmacokinetic evaluation performed for all patients.
Plasma samples were collected in heparinised tubes at
24 h and 7 days following the administration of DDP-H
and miriplatin. As reference, 50 mg/m2 (80 mg/body) of
CDDP in liquid form was administered through the
proper hepatic artery for the entire liver at a rate of
1 mg/min, and the concentration was quantified before
the administration and at 0.5, 1.0, 1.5, 2, 4, 12 and 24 h
after administration. Plasma platinum concentration was




A total of nine eligible patients were enrolled in this
study from July to October 2010 and divided into three
groups; none of the three patients from each group
developed DLT at DDP-H dose levels of 35 (level 1), 50
(level 2) and 65 (level 3) mg/m2. Patient characteristicsLevel 2 Level 3
50 65
4 5 6 7 8 9
78 61 80 63 79 80
M M M M F F
0 0 0 0 0 0
- - - + - -
- - + - + -
+ + - - - -
- - - - - +
6 6 7 5 6 6
Y Y Y Y Y Y
23 10 21 13 19 3
TACE TAC TACE TAC TACE TACE
Y Y Y Y Y Y
>5 >5 4 4 >5 >5
20 10 34 24 10 30
N N N N N N
N N N N N N
II II II II II II
AM ML M P A PA
1.5 1.72 1.68 1.415 1.538 1.538
89 121 92 83 95 85
75 86 84 92 100 100
120 60 60 74 100 120
cation: P, posterior segment; A, anterior segment; M, medial segment; L, lateral
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ance status was 0 in eight patients and 1 in one patient
(case 1). The aetiology of liver cirrhosis was HBV infec-
tion (n = 1), HCV infection (n = 4), alcoholic abuse (n = 3)
and autoimmune hepatitis (n = 1). Residual liver func-
tion was relatively good with a median Child–Pugh
score of 6, eight patients in grade A and one in grade B,
and no marked renal dysfunction was observed. All
patients had a history of HCC treatment; eight patients,
other than case 3, had a history of DDP-H-TAC fol-
lowed by epirubicin-TOCE.
The total dose of DDP-H administered was 51, 52 and
56 mg/body at level 1; 75, 84 and 86 mg/body at level 2
and 92, 100 and 100 mg/body at level 3. Total dose of
miriplatin administered was 18, 80 and 86 mg at level 1;
60, 60 and 120 mg at level 2 and 74, 100 and 120 mg at
level 3. All nine patients were assessed for toxicity of
CDDP combined with miriplatin and for the pharmaco-
kinetics of plasma platinum concentration. One patient
underwent radio frequency ablation (RFA) before re-
sponse evaluation, and thus eight patients were assessed
for anti-tumour response.Table 2 Haematological and nonhaematological toxicity
Level 1
n = 3
Hematological toxicity (grade) 1 2 3 4
White blood cell decreased 0 1 0 0
Neutrophil count decreased 0 1 0 0
Platelet count decreased 0 1 0 0
Anemia 0 1 0 0
Nonhematological toxicity (grade) 1 2 3 4
AST increased 0 1 0 0
ALT increased 0 1 0 0
Blood bilirubin increased 0 0 0 0
INR increased 0 0 0 0
Hypoalbuminemia 0 2 0 0
Creatinine increased 0 0 0 0
Anorexia 0 0 0 0
Nausea 0 0 0 0
Vomiting 0 0 0 0
Fever 1 0 0 0
Diarrhea 0 0 0 0
Fatigue 0 0 0 0
Alopecia 0 0 0 0
Urticaria 0 0 0 0
Abdominal pain 0 0 0 0
National Cancer Institute Common Terminology Criteria for Adverse Events versionToxicity
Haematological and nonhaematological toxicity in all
patients was evaluated using NCI-CTCAE (National
Cancer Institute Common Terminology Criteria for
Adverse Events) version 4.0, summarised in Table 2. No
grade ≥3 in nonhaematological or grade ≥4 in haemato-
logical toxicity was observed. One patient (case 4 in the
level 2 group) developed grade 3 neutropenia (reduced
from 3000/mm2 to 1710/mm2, 6 weeks after injection)
and subsequently recovered over 2 weeks. All three
groups showed a grade 2 increase in aspartate amino-
transferase and alanine aminotransferase (cases 3, 5, 6
and 9) and grade 1–2 hypoalbuminaemia (cases 1, 2, 5, 7
and 9). No marked increase was noted in creatinine, ex-
cept in case 7, which showed a transient increase of 1.13
times higher than baseline level 4 days after the adminis-
tration of 65 mg/m2 CDDP combined with 74 mg/body
miriplatin. The most frequent adverse event was grade 1
monophasic fever, which was observed in cases 1, 4, 8
and 9 receiving 86, 120, 100 and 120 mg/body of miri-
platin, respectively. Therefore, in this clinical study, the
MTD of CDDP in combination with miriplatin wasLevel 2 Level 3
n = 3 n = 3
Grade
1 2 3 4 1 2 3 4
0 0 1 0 0 0 0 0
0 0 1 0 0 0 0 0
0 0 0 0 2 0 0 0
0 0 0 0 0 0 0 0
1 2 3 4 1 2 3 4
1 1 0 0 0 1 0 0
1 1 0 0 0 1 0 0
1 0 0 0 1 0 0 0
0 0 0 0 0 0 0 0
0 1 0 0 1 0 0 0
0 0 0 0 1 0 0 0
0 0 0 0 1 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
1 0 0 0 2 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 1 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
4.0 was applied to evaluate toxicity.
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for DDP-H-TAC monotherapy.Pharmacokinetics of platinum
To examine whether additional miriplatin following
DDP-H administration further increases plasma plat-
inum concentration, plasma samples were collected for
pharmacokinetic studies from all nine patients at appro-
priate time periods after the administration of these
agents. Since total platinum concentration in peripheral
plasma during and after TAC in a control case, using
50 mg/m2 of CDDP administered through the hepatic ar-
tery, peaked at the end of TAC and gradually decreased
over the following 2 days (Figure 1), the plasma platinum
concentration was evaluated at the end of DDP-H-TAC
and miriplatin-TOCE and 24 h and 7 days after the initi-
ation of DDP-H-TAC. At the end of DDP-H-TAC, me-
dian Cmax for level 1, 2 and 3 groups was 2000, 2933
and 4233 ng/ml, respectively. No further increase was
detected following the administration of miriplatin: the
plasma platinum concentration gradually decreased over
7 days to 310, 456 and 580 ng/ml in level 1, 2 and 3
groups, respectively. These results indicate that the con-
centration of platinum in the plasma showed no substan-
tial increase with the addition of miriplatin to CDDP
administration, as expected.Figure 1 Platinum pharmacokinetics. Platinum concentration was
measured in all patients at three levels. Level 1, white circle; level 2,
grey circle and level 3, black circle. Plasma platinum concentration
was also measured in a 63-year-old male patient during and after
administration of CDDP (50 mg/m2 or 80 mg/body weight) for HCCs
through the proper hepatic artery at a concentration of 0.5 mg/ml
and at a flow rate of 1 mg/min (black triangle with broken line).Anti-tumour effects
Relatively good tumour control was recorded in one pa-
tient (case 3 in the level 1 group) who underwent RFA be-
fore response evaluation. Therefore, anti-tumour response
was assessed in eight patients using computed tomog-
raphy (CT) and tumour markers. Changes in the HCC
diameter and levels of α-fetoprotein (AFP) and des-γ-
carboxy prothrombin (DCP) following treatment are sum-
marised in Table 3 and Figure 2. With a median follow-up
period of 120, 87 and 83 days for level 1, 2 and 3 groups,
respectively, case 9 in the level 3 group showed a partial
response (PR) to therapy. Cases 1, 4, 6 and 8 showed
stable disease response, while cases 2, 5 and 7 showed
progressive disease response (Table 3). These changes
were consistent with the changes recorded by the tumour
markers (Figure 2). One patient (case 9) with multiple
HCC in both lobes (Figure 3a–d), who showed resistance
to previous treatment with DDP-H-TAC and epirubicin-
TACE, evidenced a PR response following combination
therapy of 65 mg/m2 of DDP-H-TAC and miriplatin-
TOCE (Figure 3e–h). Significant reduction in HCC size in
the right lobe was seen on right hepatic angiography
(Figure 3a, e). A representative tumour in S6 showed no
enhancement by CT during arterial portography (white
arrow in Figure 3b), and significant enhancement in the
early phase of CT hepatic arteriography was followed by
‘corona-like’ staining, which is a typical enhancement
pattern seen in classical HCC (white arrowheads in
Figure 3c, d) before treatment. Two months following
treatment, the remaining lipiodol (black arrow in
Figure 3f) and a marked decrease in tumour enhancement
in the area were seen (Figure 3g, h).
Discussion
Treatment for HCC was determined along with tumour
stage and hepatic functional reserve, with only 30% of
HCC cases being an indication of curative therapiesTable 3 Anti-tumour effects: clinical efficacy
Antitumor response Level 1 Level 2 Level 3
n, (Case number)
CR 0 0 0
PR 0 0 1, (Case 9)
SD 1, (Case 1) 2, (Case 4, 6) 1, (Case 8)
PD 1, (Case 2) 1 (Case 5) 1, (Case 7)
Not evaluable 1, (Case 3) 0 0
DCR (%) 50 66.7 66.7
Period of follow up (day)
Median 120 87 83
Range 50-213 24-140 54-84
Modified Response Evaluation Criteria In Solid Tumors guidelines were
followed to evaluate anti-tumour effects. CR, complete response; PR, partial
response; SD, stable disease; PD, progressive disease; DCR, disease control rate.
Figure 2 Anti-tumour effects: levels of tumour markers. Time-dependent levels of α-fetoprotein (a–c) and des-γ-carboxy prothrombin (d–f)
after combination therapy of IA-call
W
and miriplatin at levels 1 (a, d), 2 (b, e) and 3 (c, f). Tumour markers are represented as white circles in cases
1, 4 and 7; grey circles in cases 2, 5 and 8 and black circles in cases 3, 6 and 9. PR, partial response; SD, stable disease; PD, progressive disease; N/A, not
applicable for the response evaluation.
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sorafenib have recently been reported to show a defin-
ite survival advantage in advanced cases [3,4,6-8,28].
Unfortunately, however, the application of TACE or
sorafenib is strictly restricted by other factors, mainly
hepatic functional reserve. TACE requires a Child–
Pugh score of 5–9, grade A–B, for hepatic function as
it involves arterial embolization and may not be com-
pleted in a patient with major arterioportal shunts or
portal vein tumour thrombosis. Sorafenib is contraindi-
cated in patients with the exceptions of Child–Pugh
score of 5–6, grade A or with brain metastases [2].
In contrast, TOCE and TAC can be provided over a broad
range of cases as these are performed without
arterial embolization and their efficacy has been reported
[5,13-15,26]. Among various chemotherapeutic agents
such as epirubicin [15] and mitomycin C [5], which carry
a 15%–20% response rate, platinum agents appear to be
the most promising as CDDP-TAC achieved a response
rate of 33.8% in a multicentre phase II study enrolling
unresectable HCC cases [13]. To investigate the highly ef-
fective and less toxic combination of TOCE and TAC, this
study focused on safety issues associated with the con-
comitant use of two platinum agents.
Miriplatin is a third-generation platinum agent with
amphipathic properties that forms a stable suspension
with lipiodol and gradually releases active derivatives in
situ, which circumvents systematic release and toxicity
[18]. Treatment in few HCC cases has shown cross-resistance with different generations of platinum agents
[16,21,29]. In a rat model, miriplatin exhibited higher
anti-tumour activity and lower hepatic toxicity than
CDDP-lipiodol [16], and promising results have been
reported in HCC patients [22-24]. On the other hand,
clearance of platinum compounds following short-term
intravenous infusion of cisplatin was reported as tripha-
sic (distribution half-life, 13 min; elimination half-life,
43 min and terminal half-life, 5.4 days). The short distri-
bution half-life suggests that TAC easily exceeds tissue
distribution speed and saturates the target liver on the
basis of concentration rather than the total amount of
the drug administered. Accordingly, DDP-H is currently
the most suitable form of platinum agent for TAC by
providing the highest concentration available. The com-
bination of DDP-H-TAC and miriplatin-TOCE supports
the hypothesis that higher the free platinum concentra-
tion in the target liver, lesser the systemic spill over and
more sustained delivery achieved by a less cross-resistant
agent leads to marked tumour response and less toxicity
(both systemic and hepatic), leading to improvement in
survival rates.
Conclusions
In conclusion, in this study, no DLT was recorded following
the combined administration of DDP-H and miriplatin at a
maximum dose of 65 mg/m2 and 120 mg/body, respect-
ively. These are the maximum doses recommended for
each monotherapy individually, indicating that the MTD
Figure 3 Representative images of tumour from case 9 showing partial response after administration of DDP-H TAC and
miriplatin-TOCE. Before treatment: a, right hepatic angiography; b, computed tomography during arterial portography (CTAP). White arrow
indicates tumour defect on CTAP; c, early phase of CT hepatic arteriography (CTHA); d, delayed phase of CTHA. White arrowheads indicate
staining of tumour. Two months after treatment: e, right hepatic angiography; f, plain CT image; g, early phase of dynamic CT; h, delayed phase
of dynamic CT. Black arrow indicates remaining lipiodol.
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http://www.biomedcentral.com/1471-230X/12/127of DDP-H and miriplatin in combination therapy is the
maximum monotherapy dose. No evidence of systemic
platinum release from miriplatin-TOCE was recorded, as
expected. Reflecting a possible higher disease control rate
and PR response, a phase II randomised prospective
study is now ongoing to investigate the efficacy of this
combined therapy in a larger cohort.
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